Abstract 183P
Background
In Asia, the standard treatment for locally advanced gastric cancer (LAGC) involves gastrectomy with D2 dissection and adjuvant chemotherapy. However, achieving adequate chemotherapy intensity after gastrectomy presents challenges. Previous trials have shown the effectiveness of neoadjuvant chemotherapy (NAC). Nevertheless, limited research has been conducted to explore the feasibility of NAC-SOX for older patients with LAGC. This phase II study (KSCC1801) aimed to assess the safety and efficacy of NAC-SOX in LAGC patients aged ≥ 70 years. Herein, we present the conclusive data analysis of KSCC1801, shedding light on its outcomes.
Methods
Patients received NAC consisting of three cycles of SOX130 (oxaliplatin 130 mg/m2 on day 1, oral S-1 40-60 mg twice daily for two weeks every three weeks), followed by gastrectomy with lymph node dissection. The primary endpoint was the dose intensity (DI) of the treatment. Secondary endpoints included safety, R0 resection rate, pathological response rate (pRR), overall survival, and relapse-free survival.
Results
The study enrolled 26 patients with a median age of 74.5 years. The median DI in the NAC-SOX130 treatment was 97.2% for S-1 and 98.3% for oxaliplatin. NAC was successfully administered to 25 patients (96.2%), among whom 24 (92.3%) underwent gastrectomy with lymphadenectomy. The R0 resection rate was 92.3%, and the pRR (≥ grade 1b) was 62.5%. Major adverse events (≥ grade 3) included neutropenia (20.0%), thrombocytopenia (11.5%), anorexia (11.5%), nausea (7.7%), and hyponatremia (7.7%). Postoperative complications such as abdominal infection, elevated blood amylase, and bacteremia occurred in one patient each. The 1- and 2-year OS rates were 93.3% and 89.7%, respectively. The 1- and 2-year RFS rates were 68.7% and 58.6%, respectively.
Conclusions
NAC-SOX130 proves to be a feasible therapy for older patients aged ≥ 70 years.
Clinical trial identification
jRCTs071180001.
Editorial acknowledgement
Legal entity responsible for the study
KSCC (Kyushu Study group of Clinical Cancer).
Funding
Yakult Honsha.
Disclosure
E. Oki: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Bayer, Eli Lilly, Bristol-myers Squibbb, MSD; Financial Interests, Personal and Institutional, Research Grant: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract